--- title: "Palisade Bio (PALI) news: going concern and offering" url: "https://aibio.space/companies/palisade-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PALI going concern, offering and Nasdaq notice news: Palisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance." --- PALI Palisade Bio, Inc. NASDAQ · United States # Palisade Bio (PALI) news PALI going concern, offering and Nasdaq notice news Company Updates · 2026-08-10 ## [Palisade Bio reports second quarter 2026 results and Phase 2 plans for PALI-2108](https://aibio.space/news/palisade-bio-reports-second-quarter-2026-results-phase-2-plans-pali/) The company reported a net loss of $10.6 million for the quarter and cash of $125.2 million at June 30, 2026. It expects to start the Phase 2 ASCENTRA-UC trial in the second half of 2026. ## Latest Palisade Bio news 1. 2026-06-10 Company Updates [Palisade Bio adds Jordan Zwick to its board and raises authorized shares](https://aibio.space/news/palisade-bio-adds-jordan-zwick-board-raises-authorized-shares/) The annual meeting on June 10, 2026 approved raising authorized common stock from 300,000,000 to 450,000,000 shares. Stockholders also approved two amended equity plans. 2. 2026-05-12 Company Updates [Palisade Bio reports first quarter 2026 results and $132.6 million in cash](https://aibio.space/news/palisade-bio-reports-first-quarter-2026-results-132-6-million-cash/) The company reported cash and cash equivalents of $132.6 million at March 31, 2026. It said the Phase 2 ulcerative colitis trial of PALI-2108 is expected to start in the third quarter of 2026. 3. 2026-03-27 Financings [Palisade Bio sells $3.0 million of stock to an affiliate of Iterative Health](https://aibio.space/news/palisade-bio-sells-3-0-million-stock-affiliate-iterative-health/) The company sold 1,536,885 shares at $1.952 per share, with the sale closing on March 27, 2026. It also signed an agreement with Iterative Health to help enroll patients in its planned Phase 2 ulcerative colitis study. 4. 2025-07-25 Financings [Palisade Bio sets $0.9047 warrant inducement for about $3.9 million in gross proceeds](https://aibio.space/news/palisade-bio-sets-0-9047-warrant-inducement-about-3-9-million-gross/) A holder will exercise 4,318,905 Palisade warrants at a reduced price and receive new warrants for up to 8,637,810 shares. Ladenburg Thalmann is the placement agent. 5. 2025-05-02 Listings [Palisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance](https://aibio.space/news/palisade-bio-gets-nasdaq-minimum-bid-price-deficiency-notice-has-180/) Palisade Bio received a Nasdaq minimum bid price notice on April 30, 2025, after its stock closed below $1.00 for 30 consecutive trading days. It has 180 calendar days to regain compliance, and its 2024 annual report carries a going-concern warning alongside $9.8 million of cash. 6. 2025-05-02 Listings [Palisade Bio gets Nasdaq notice for trading below $1.00 minimum bid price](https://aibio.space/news/palisade-bio-gets-nasdaq-notice-trading-below-1-00-minimum-bid-price/) Palisade Bio has 180 calendar days from an April 30, 2025 Nasdaq notice to get its shares back above $1.00, and its lead candidate is still in a Phase 1 study. ## Palisade Bio at a glance - **Ticker**: PALI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $125.2 million ### Related companies - [Capricor Therapeutics](https://aibio.space/companies/capricor-therapeutics/) NASDAQ: CAPR - [Ironwood Pharmaceuticals](https://aibio.space/companies/ironwood-pharmaceuticals/) NASDAQ: IRWD - [Rigel Pharmaceuticals](https://aibio.space/companies/rigel-pharmaceuticals/) NASDAQ: RIGL - [Tevogen](https://aibio.space/companies/tevogen/) NASDAQ: TVGN - [Lipocine](https://aibio.space/companies/lipocine/) NASDAQ: LPCN - [MERA PHARMACEUTICALS INC](https://aibio.space/companies/mera-pharmaceuticals/) OTC: MRPI - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) NASDAQ: CGEM - [Savara](https://aibio.space/companies/savara/) NASDAQ: SVRA ### Also on NASDAQ - [LAKELAND INDUSTRIES INC](https://aibio.space/companies/lakeland-industries/) LAKE - [RenovoRx](https://aibio.space/companies/renovorx/) RNXT - [Agenus](https://aibio.space/companies/agenus/) AGEN - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) SRRK - [Viridian Therapeutics](https://aibio.space/companies/viridian-therapeutics/) VRDN - [Seaport Therapeutics](https://aibio.space/companies/seaport-therapeutics/) SPTX ## Palisade Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | | [$16.0 million](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000004/) | | Net income (loss) | [-$16.8 million](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000004/) | [-$14.4 million](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000004/) | | Cash from operations | [-$10.8 million](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000004/) | [-$12.2 million](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000004/) | | Cash and equivalents | [$133.4 million](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000016/) | [$9.8 million](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000004/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $125.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Palisade Bio Has Palisade Bio issued a going-concern warning? Our latest story on this, dated May 2, 2025: "Palisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/palisade-bio-gets-nasdaq-minimum-bid-price-deficiency-notice-has-180/). Has Palisade Bio raised money recently? Our latest story on this, dated Mar 27, 2026: "Palisade Bio sells $3.0 million of stock to an affiliate of Iterative Health". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/palisade-bio-sells-3-0-million-stock-affiliate-iterative-health/). Has Palisade Bio received a Nasdaq deficiency notice? Our latest story on this, dated May 2, 2025: "Palisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/palisade-bio-gets-nasdaq-minimum-bid-price-deficiency-notice-has-180/). What is the ticker symbol of Palisade Bio? Palisade Bio, Inc. trades under the ticker PALI on NASDAQ. Where is Palisade Bio listed? Palisade Bio, Inc. is listed on NASDAQ. What is the SEC CIK of Palisade Bio? The SEC Central Index Key (CIK) for Palisade Bio, Inc. is 1357459. Its filings are on SEC EDGAR. How many shares does Palisade Bio have outstanding? 174,270,558 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Palisade Bio listed under? Our directory records Palisade Bio, Inc. under United States. What does Palisade Bio do? Our directory classifies Palisade Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Palisade Bio? The ISIN recorded for Palisade Bio, Inc. is US6963894026. Does aibio.space cover Palisade Bio? aibio.space lists Palisade Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Palisade Bio incorporated? SEC records list its state or country of incorporation as DE. Is Palisade Bio profitable? Palisade Bio, Inc. reported a net loss of $16.8 million for the fiscal year ended Dec 31, 2025, and used $10.8 million of cash in operations, per its annual report to the SEC. How much cash does Palisade Bio have? $125.2 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Palisade Bio (PALI) stock news? Our latest story on Palisade Bio, dated Aug 10, 2026: "Palisade Bio reports second quarter 2026 results and Phase 2 plans for PALI-2108". The company reported a net loss of $10.6 million for the quarter and cash of $125.2 million at June 30, 2026. It expects to start the Phase 2 ASCENTRA-UC trial in the second half of 2026. [Source](https://aibio.space/news/palisade-bio-reports-second-quarter-2026-results-phase-2-plans-pali/). ## Investor discussion: Palisade Bio Members talk about Palisade Bio (PALI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Palisade Bio, newest first. Each line links the filing it comes from. 1. 2026-06-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1357459/000149315226028322/form8-k.htm) 2. 2025-12-04 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1357459/000149315225026195/form8-k.htm) 3. 2025-10-20 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1357459/000149315225018684/form8-k.htm) 4. 2025-10-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1357459/000149315225018324/form8-k.htm) 5. 2025-09-29 Financings Filed a final prospectus for a securities offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1357459/000149315225015872/forms-1.htm) 6. 2025-09-15 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1357459/000149315225013379/formdef14a.htm) 7. 2025-09-05 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1357459/000149315225012677/formpre14a.htm) 8. 2025-05-27 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1357459/000164117225012405/forms-1.htm) 9. 2025-05-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1357459/000164117225008346/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PALI on TradingView](https://www.tradingview.com/symbols/NASDAQ-PALI/). ## SEC filings and registration - **SEC name**: Palisade Bio, Inc. - **CIK**: 1357459 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: PALI (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009 - **Phone**: (858) 704-4900 - **Shares outstanding**: 174,270,558 as of 2026-08-06 (10-Q filed 2026-08-10) - **Former names**: PALISADE BIO, INC.; Seneca Biopharma, Inc.; Neuralstem, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-20260810.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000016/pali-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1357459/000149315226028322/form8-k.htm) filed 2026-06-11 - [S-3](https://www.sec.gov/Archives/edgar/data/1357459/000149315226022548/forms-3.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000011/pali-20260512.htm) filed 2026-05-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1357459/000135745926000010/pali-20260331.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1357459/000149315226019629/formdef14a.htm) filed 2026-04-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1357459/000149315226014822/form8-k.htm) filed 2026-04-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001357459), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Palisade Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PALI, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Palisade Bio, Inc. - **Ticker**: PALI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6963894026 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PALI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/palisade-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Palisade Bio (PALI) news: going concern and offering", 2026-10-31, https://aibio.space/companies/palisade-bio/